Compare Comcast Corporation (CMCSA) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Enveric Biosciences Inc — how do they compare? Comcast Corporation trades at $25.6 (market cap $89.43B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Comcast Corporation is far larger — about 14424.2× Enveric Biosciences Inc's market cap, and Comcast Corporation pays a 5.24% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| CMCSA | ENVB | |
|---|---|---|
Market Cap | $89.43B | $6.20M |
Sector | Media | Health |
52-Week High | $32.50 | $17.40 |
52-Week Low | $21.92 | $1.27 |
Enterprise Value | $172.15B | $1.30M |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.36, up 0.75% today, with strong technical momentum showing bullish moving averages and support at $25. The company demonstrates robust fundamentals with a low P/E of 8.13 and consistent earnings beats, including Q2 2026 EPS of $1.04 versus $0.97 expected. Recent expansion announcements in Florida and New Hampshire highlight ongoing growth initiatives.
CMCSA presents compelling value with discounted valuation multiples and a 55.74% analyst buy rating. Key opportunities include wireless growth and Peacock profitability, while risks involve competitive pressures and the planned NBCUniversal spinoff. The consensus price target of $27.78 suggests 9.5% upside potential from current levels.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
